Interplays between mouse mammary tumor virus and the cellular and humoral immune response

Immunological Reviews

Volumn 168, Issue , 1999, Pages 287-303

  Acha Orbea, Hans ^a   Finke, Daniela ^a   Attinger, Antoine ^a   Schmid, Sandie ^a   Wehrli, Nathalie ^a   Vacheron, Sonia ^a   Xenarios, Ioannis ^a   Scarpellino, Leonardo ^a   Toellner, Kai Michael ^b   MacLennan, Ian C M ^b   Luther, Sanjiv A ^a,c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; SUPERANTIGEN;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; GERMINAL CENTER; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PEYER PATCH; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS INFECTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, VIRAL; HUMANS; IMMUNITY, CELLULAR; MAMMARY TUMOR VIRUS, MOUSE; MICE; MOLECULAR SEQUENCE DATA; RETROVIRIDAE INFECTIONS; SUPERANTIGENS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR VIRUS INFECTIONS; VIRUS DISEASES;

EID: 0033000063     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01299.x     Document Type: Review

References (130)

1. 1. Nusse R, Varmus HE. Wnt genes. Cell 1992;69:1073-1087.
2. 2. Nandi S, McGrath C M. Mammary neoplasia in mice. Adv Cancer Res 1973;17:353-414.
3. 3. Bentvelzen P, Hilgers J. Murine mammary tumor virus. In: Klein G. ed. Viral oncology. New York: Raven Press; 1980. p. 311-355.
4. 4. Luther SA, Acha-Orbea H. Mouse mammary tumor virus: immunological interplays between virus and host. Adv Immunol 1997;65:139-243.
5. 5. Choi Y, Kappler JW, Marrack P. A superantigen encoded in the open reading frame of the 3' long terminal repeat of mouse mammary tumor virus. Nature 1991;350:203-207.
6. β14 positive T cells in mammary tumor virus transgenic mice. Nature 1991;350:207-211.
7. 7. Fields BA, et al. Crystal structure of a T-cell receptor β-chain complexed with a superantigen. Nature 1996;384:188-192.
8. 8. White J, Herman A, Pullen AM, Kubo R, Kappler JW, Marrack P. The Vβ-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. Cell 1989;56:27-35.
9. β usage of the responder cells. J Immunol 1990;144:1181-1186.
10. 10. Janeway CA Jr, et al. T-cell responses to Mls and to bacterial proteins that mimic its behavior. Immunol Rev 1989;107:61-88.
11. 11. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990;248:705-711.
12. 12. Yazdanbakhsh K, Park CG, Winslow GM, Choi Y. Direct evidence for the role of COOH terminus of mouse mammary tumor virus superantigen in determining T cell receptor V beta specificity. J Exp Med 1993;178:737-741.
13. 13. Karapetian O, Shakhov AN, Kraehenbuhl JP, Acha-Orbea H. Retroviral infection of neonatal Peyer's patch lymphocytes: the mouse mammary tumor virus model. J Exp Med 1994;180:1511-1516.
14. + T cells in an Mls-1b BALB/c colony infected with an exogenous mouse mammary tumor virus. J Immunol 1993;151:759-766.
15. 15. Desaymard C, Tucek CL, Rocha B, Korman AJ, Papiernik M. Tissue distribution of Mtv-7-like exogenous retroviral transcripts and clonal deletion of Vβ 6+ T cells in Mls-1b BALB/c mice. Int Immunol 1993;5:217-222.
16. 16. Held W, Waanders GA, Shakhov AN, Scarpellino L, Acha-Orbea H, MacDonald HR. Superantigen-induced immune stimulation amplifies mouse mammary tumor virus infection and allows virus transmission. Cell 1993;74:529-540.
17. + T cells are required to stimulate B cells after infection with mouse mammary tumor virus. J Exp Med 1993;177:359-366.
18. 18. Held W, Waanders GA, Acha-Orbea H, MacDonald HR. Reverse transcriptase-dependent and -independent phases of infection with mouse mammary tumor virus: implications for superantigen function. J Exp Med 1994;180:2347-2351.
19. 19. Luther SA, Gulbranson-Judge A, Acha-Orbea H, MacLennan IC. Viral superantigen drives extrafollicular and follicular B cell differentiation leading to virus-specific antibody production. J Exp Med 1997;185:551-562.
20. 10. Beutner U, Kraus E, Kitamura D, Rajewsky K, Huber BT. B cells are essential for murine mammary tumor virus transmission, but not for presentation of endogenous superantigens. J Exp Med 1994;179:1457-1466.
21. 21. Zack JA. The role of the cell cycle in HIV-1 infection Adv Exp Med Biol 1995;374:27-31.
22. 22. Zack JA, Haislip AM, Krogstad P, Chen IS. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol 1992;66:1717-1725.
23. 23. Bukrinsky MI, et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993;365:666-669.
24. 24. Ardavin C, et al. Retrovirus-induced target cell activation in the early phases of infection: the mouse mammary tumor virus model. J Virol 1997;71:7295-7299.
25. 25. Finke D, Mortezavi L, Acha-Orbea H. Preactivation of B lymphocytes does not enhance mouse mammary tumor virus infection. J Virol 1998;72:7688-7691.
26. 2 determinants. J Exp Med 1990;171:953-958.
27. 27. Larsson-Sciard EL, Spetz-Haigberg AL, Casrouge A, Kourilsky P. Analysis of T cell receptor Vβ gene usage in primary mixed lymphocyte reactions: evidence for directive usage by different antigen-presenting cells and Mls-like determinants on T cell blasts. Eur J Immunol 1990;20:1223-1229.
28. 2-encoded determinants. J Exp Med 1990;171:1381-1386.
29. a determinants involves major histocompatibility complex class II molecules. J Exp Med 1991;173:779-782.
30. 30. Braun MY, Jouvin-Marche E, Marche PN, MacDonald HR, Acha-Orbea H. T cell receptor V β repertoire in mice lacking endogenous mouse mammary tumor provirus. Eur J Immunol 1995;25:857-862.
31. 31. Gollob KJ, Palmer E. Physiologic expression of two superantigens in the BDF1 mouse. J Immunol 1991;147:2447-2454.
32. 32. Toellner KM, et al. T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J Exp Med 1998;187:1193-1204.
33. 33. Banchereau J, et al. Dendritic cells and the control of immunity: phenotypic analysis of antigen-specific T lymphocytes. Nature 1998;392:245-252.
34. 34. Champagne E, Scarpellino L, Lane P, Acha Orbea H. CD28/CTLA4-B7 interaction is dispensable for T cell stimulation by mouse mammary tumor virus superantigen but not for B cell differentiation and virus dissemination. Eur J Immunol 1996;26:1595-1602.
35. 35. Le Bon A, Lucas B, Vasseur F, Penit C, Papiernik M. In vivo T cell response to viral superantigen. Selective migration rather than proliferation. J Immunol 1996;156:4602-4608.
36. 36. Palmer LD, Saha B, Hodes RJ, Abe R. The role of CD28 costimulation in immune-mediated responses against mouse mammary tumor viruses. J Immunol 1996;156:2112-2118.
37. 37. Luther SA, Maillard I, Luthi F, Scarpellino L, Diggelmann H, Acha-Orbea H. Early neutralizing antibody response against mouse mammary tumor virus: critical role of viral infection and superantigen-reactive T cells. J Immunol 1997;159:2807-2814.
38. 38. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998;8:363-372.
39. 39. Tsubura A, et al. Intervention of T-cells in transportation of mouse mammary tumor virus (milk factor) to mammary gland cells in vivo. Cancer Res 1988;48:6555-6559.
40. 40. Golovkina TV, Chervonsky A, Dudley JP, Ross SR. Transgenic mouse mammary tumor virus superantigen expression prevents viral infection. Cell 1992;69:637-645.
41. 41. Chervonsky AV, Xu J, Barlow AK, Khery M, Flavell RA, Janeway CA Jr. Direct physical interaction involving CD40 ligand on T cells and CD40 on B cells is required to propagate MMTV. Immunity 1995;3:139-146
42. 42. Kearney ER, Pope KA, Loh DY, Jenkins MK. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1994;1:327-339.
43. 43. McHeyzer-Williams MG, Altman JD, Davis MM. Enumeration and characterization of memory cells in the TH compartment. Immunol Rev 1996;150:5-21.
44. 44. Golovkina TV, Dudley JP, Jaffe AB, Ross SR. Mouse mammary tumor viruses with functional superantigen genes are selected during in vivo infection. Proc Natl Acad Sci USA 1995;92:4828-4832.
45. 45. Waanders GA, Shakhov AN, Held W, Karapetian O, Acha-Orbea H, MacDonald HR. Peripheral T cell activation and deletion induced by transfer of lymphocyte subsets expressing endogenous or exogenous mouse mammary tumor virus. J Exp Med 1993;177:1359-1366.
46. 46. Ardavin C, Martin P, Ferrero I, Azcoitia I, Luther SA, Acha-Orbea H. B220 versus MHC class II expression identifies responding B cells after infection with the mouse mammary tumor virus. J Immunol 1999;162:2538-2545.
47. 47. Webb S, Morris C, Sprent J. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 1990;63:1249-1256.
48. a expressing cells. Nature 1989;339:541-544.
49. 49. Ignatowicz L, Kappler J, Marrack P. The effects of chronic infection with a superantigen-producing virus. J Exp Med 1992;175:917-923.
50. b mice. J Exp Med 1992;175:453-460.
51. a (Mtv-7). J Exp Med 1992;175:1623-1633.
52. 52. Marrack P, Kushnir E, Kappler J. A maternally inherited superantigen encoded by a mammary tumor virus. Nature 1991;349:524-526.
53. 53. Held W, Waanders GA, MacDonald HR, Acha-Orbea H. MHC class II hierarchy of superantigen presentation predicts efficiency of infection with mouse mammary tumor virus. Int Immunol 1994;6:1403-1407.
54. 54. Kappler JW, Staerz UD, White J, Marrack PC. Self-tolerance eliminates T cells specific for Mls-modified products of the major histocompatibility complex. Nature 1988;332:35-40.
55. a-encoded antigens. Immunol Rev 1989;107:89-108.
56. 56. Papiernik M, et al. T cell deletion induced by chronic infection with mouse mammary tumor virus spares a CD25-positive, IL-10-producing T cell population with infectious capacity. J Immunol 1997;158:4642-4653.
57. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-296.
58. 58. McHeyzer-Williams MG, Altman JD, Davis MM. Tracking antigen-specific helper T cell responses. Curr Opin Immunol 1996;8:278-284.
59. + T cells upon acute versus persistent viral infection. Immunity 1998;9:449-457.
60. 60. Fugier-Vivier I, Servet-Delprat C, Rivailler P, Rissoan MC, Lui YJ, Rabourdin-Combe C. Measles virus suppresses cell mediated immunity by interfering with the survival and functions of dendritic and T cells. J Exp Med 1997;186:813-823.
61. + T cells. J Exp Med 1997;186:801-812.
62. 62. Altman JD, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274;94-96.
63. + T cells during an acute virus infection. Immunity 1998;8:167-175.
64. 64. Gallimore A, et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med 1998;187:1383-1393.
65. 65. Murali-Krishna K, et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998;8:177-187.
66. 66. Gotch FM, Nixon DF, Alp N, McMichael AJ, Borysiewicz LK. High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals. Int Immunol 1990;2:707-712.
67. 67. Rehermann B, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995;181:1047-1058.
68. 68. Rehermann B, et al. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 1996;70:7092-7102.
69. 69. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104-1108.
70. 70. Kuroda MJ, et al. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med 1998;187:1373-1381.
71. + T cells with a predominant Vβ usage during the primary immune response to HIV. Nature 1994;370:463-467.
72. + T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998;187:1395-1402.
73. + T cells in acute infectious mononucleosis. Nat Med 1996;2:906-911.
74. 74. Borrow P, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997;3:205-211.
75. + T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 1997;159:105-117.
76. + T cells in primary and secondary influenza pneumonia. Immunity 1998;8:683-691.
77. 77. MacDonald HR, Casanova JL, Maryanski JL, Cerottini JC. Oligoclonal expansion of major histocompatibility complex class I-restricted cytolytic T lymphocytes during a primary immune response in vivo: direct monitoring by flow cytometry and polymerase chain reaction. J Exp Med 1993;177:1487-1492.
78. 78. Maryanski JL, Jongeneel CV, Bucher P, Casanova JL, Walker PR. Single-cell PCR analysis of TCR repertoires selected by antigen in vivo: a high magnitude CD8 response is comprised of very few clones. Immunity 1996;4:47-55.
79. 79. Walker PR, Wilson A, Bucher P, Maryanski JL. Memory TCR repertoires analyzed long-term reflect those selected during the primary response. Int Immunol 1996;8:1131-1138.
80. + T cell response depending on the route of immunization. J Immunol 1998;160:5522-5529.
81. + T cell responses to an immunodominant Moloney leukemia virus-encoded epitope in vivo. J Immunol 1998;160:1659-1665.
82. 82. Wei WZ, Malone K, Mahoney K, Heppner G. Characterizations of lymphocytic infiltrates in normal, preneoplastic, and neoplastic mouse mammary tissues. Cancer Res 1986;46:2680-2685.
83. 83. Blair PB, Line MA. In vitro detection of immune responses to Mtv-induced mammary tumors: qualitative differences in response detected by time studies. J Immunol 1975;114:17-23.
84. 84. Heppner GH, Kopp JS, Medina D. Microcytotoxicity assay of immune responses to non-mammary tumor virus-induced, preneoplastic, and neoplastic mammary lesions in BALB/c mice. Cancer Res 1976;36:753-758.
85. 85. Stutman O. Natural and induced immunity to mouse mammary tumors and the mammary tumor virus (MuMTV). Springer Semin Immunopathol 1982;4:333-372.
86. + cells but fails to trigger cytotoxicity. Eur J Immunol 1992;22:2789-2793.
87. 87. Valitutti S. Muller S, Dessing M, Lanzavecchia A. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med 1996;183:1917-1921.
88. 88. Hemmer B, Stefanova I, Vergelli M, Germain RN, Martin R. Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. J Immunol 1998;160:5807-5814.
89. 89. Wei WZ, Gill RF, Jones RF, Lichlyter D, Abastado JP. Induction of cytotoxic T lymphocytes to murine mammary tumor cells with a Kd-restricted immunogenic peptide. Int J Cancer 1996;66:659-663.
90. 90. Gill RF, Abastado JP, Wei WZ. Systematic identification of H-2 Kd binding peptides and induction of peptide specific CTL. J Immunol Methods 1994;176:245-253.
91. 91. Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998;188:1203-1208.
92. 92. Stockert E, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-1354.
93. 93. Overwijk WW, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998;188:277-286.
94. 94. Romero P, et al. Ex vivo staining of metastatic lymph nodes by MHC class I MHC tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998;188:1641-1650.
95. 95. Dyall R, et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998;188:1553-1562.
96. 96. Valmori D, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998;160:1750-1758.
97. + T cells by B7-transfected melanoma cells. Science 1993;259:368-370.
98. + T-cell-stimulating peptide presented by a major histocompatibility complex class I molecule in a murine thymoma. Proc Natl Acad Sci USA 1996;93:13991-13996.
99. 99. Dzuris JL, Golovkina TV, Ross SR. Both T and B cells shed infectious mouse mammary tumor virus. J Virol 1997;71:6044-6048.
100. 100. Gill R, Wang H, Bluethmann H, Iglesias A, Wei WZ. Activation of natural killer cells by mouse mammary tumor virus C4 in BALB/c and T-cell receptor Vβ2-transgenic mice. Cancer Res 1994;54:1529-1535.
101. 101. Wei W-Z, Heppner G. Natural killer activity of lymphocyte infiltrates in mouse mammary lesions. Br J Cancer 1987;55:589-594.
102. 102. Wei WZ, Gill RF, Wang H. Mouse mammary tumor virus associated antigens and superantigens - immuno-molecular correlates of neoplastic progression. Semin Cancer Biol 1993;4:205-213.
103. + T-cell-deficient mice survive inoculation with high doses of vaccinia virus and exhibit altered IgG responses: mechanism of antigen-driven selection in germinal centres. Proc Natl Acad Sci USA 1992;89:6070-6074.
104. + T lymphocytes because of disruption of the β 2-microglobulin gene. J Virol 1993;67:332-339.
105. 105. Raulet DH. MHC class II deficient mice. Adv Immunol 1994;55:381-421.
106. 106. Maillard I, Launois P, Xenarios I, Louis JA, Acha-Orbea H, Diggelmann H. Immune response to mouse mammary tumor virus in mice lacking the α/β interferon or the γ interferon receptor. J Virol 1998;72:2638-2646.
107. 107. Andersson M, Paabo S, Nilsson T, Peterson PA. Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance. Cell 1985;43:215-222.
108. 108. Burgert HG, Kvist S. An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell 1985;41:987-997.
109. 109. Rotem-Yehudar R, Groettrup M, Soza A, Kloetzel PM, Ehrlich R. LMP-associated proteolylic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. J Exp Med 1996;183:499-514.
110. 110. Frūh K, et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995;375:415-418.
111. 111. Hill A, et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995;375:411-415.
112. 112. Wiertz EJ, et al. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 1996;384:432-438.
113. 113. Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 1996;84:769-779.
114. 114. Gilbert MJ, Riddell SR, Plachter B, Greenberg PD. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 1996;383:720-722.
115. 115. Reyburn HT, Mandelboim O, Vales-Gomez M, Davis DM, Pazmany L, Strominger JL. The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature 1997;386:514-517.
116. 116. Levitskaya J, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995;375:685-688.
117. 117. Smith GL, Symons JA, Khanna A, Vanderplasschen A, Alcami A. Vaccinia virus immune evasion. Immunol Rev 1997;159:137-154.
118. 118. Luescher IF, Anjuere F, Peitsch MC, Jongeneel CV, Cerottini JC, Romero P. Structural analysis of TCR-ligand interactions studied on H-2Kd-restricted cloned CTL specific for a photoreactive peptide derivative. Immunity 1995;3:51-63.
119. 119. Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan IC. Mechanism of antigen-driven selection in germinal centres. Nature 1989;342:929-931.
120. 120. Papiernik M, Wache AC, Pontoux C, Nabarra B. Massive mammary gland infection and pregnancy-dependent mammary tumor development in mice infected neonatally with mouse mammary tumor virus (SW) but not in mice infected as adults, despite a dramatic local response. Eur J Immunol 1997;27:2145-2151.
121. 121. Callahan R, Sherr CJ, Todaro GJ. A new class of murine retroviruses: immunological and biochemical comparison of novel isolates from Mus cervicolor and Mus coroli. Virology 1977;80:401-416.
122. 122. Morris VL, Medeiros E, Ringold GM, Bishop JM, Varmus HE. Comparison of mouse mammary minor virus-specific DNA in inbred, wild and Asian mice, and in tumors and normal organs from inbred mice. J Mol Biol 1977;114:73-91.
123. μ genes in natural populations of mice. Eur J Immunol 1989;19:1921-1926.
124. 124. Bakhanashvili M, Hizi A. The fidelity of the reverse transcriptases of human immunodeficiency viruses and murine leukemia virus, exhibited by the mispair extension frequencies, is sequence dependent and enzyme related. FEBS Lett 1993;319:201-205.
125. 125. Majors JE, Varmus HE, Lehmann Grube F, Lohler J, Utermohlen O, Gegin C. Nucleotide sequencing of an apparent proviral copy of env mRNA defines determinants of expression of the mouse mammary tumor virus env gene. J Virol 1983;47:495-504.
126. 126. Vartanian JP, Meyerhans A, Sala M, Wain-Hobson S. G→A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc Natl Acad Sci USA 1994;91:3092-3096.
127. 127. Vartanian JP, Meyerhans A, Asjo B, Wain-Hobson S. Selection, recombination, and G→A hypermutation of human immunodeficiency virus type 1 genomes. J Virol 1991;65:1779-1788.
128. 128. Golovkina TV, Piazzon I, Nepomnaschy I, Buggiano V, de Olano Vela M, Ross SR. Generation of a tumorigenic milk-borne mouse mammary tumor virus by recombination between endogenous and exogenous viruses. J Virol 1997;71:3895-3903.
129. 129. Nishio M, et al. Complete nucleotide seuqence of mouse mammary tumor virus from JYG Chinese wild mice: absence of bacterial insertion sequences in the cloned viral gag gene. Breast Cancer 1994;1:89-94.
130. 130. Zinkernagel RM, Bachmann MF, Kundig TM, Oehen S, Pirchet H, Hengartner H. On immunological memory. Annu Rev Immunol 1996;14:333-367.